News
Four new articles from the NIH Technology Transfer Community have been published in the most recent edition of les Nouvelles, the Licensing Executive Society’s journal. NIH is not just a funder of science but is a critical catalyst that helps transform bold ideas into treatments that reach patients
Currently, there is no effective treatment for many types of retinal degeneration. Nor are there sufficient treatments for autoimmune uveitis, as current uveitis treatment primarily uses steroidal anti-inflammatory medication, which can produce significant unwanted side effects with long-term use
NIH inventors have developed an image-based machine learning system that is able to validate functional cell phenotypes. The system may be trained to automatically recognize image features that correlate with a desired cell-type or properties for research, diagnostic, and therapeutic purposes. This
NIH inventors have developed a mutation-independent method to treat Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), other inherited retinal degenerations (IRDs), and age-related macular degeneration (AMD) using the FDA-approved small molecule, Halofantrine. NIH inventors found